furaprevir
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01523990)
Timeline
Indications
Mechanism of action
A3EZI9 inhibitor
Hepatitis C virus serine protease, NS3/NS4A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)Oc1ccc(-c2nc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)c3oc4ccccc4c3n2)cc1- Mol. weight
- 897.06 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297647 ↗
Also known as
- furaprevir
- tg-2349
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04155515 | Phase 3 | Jun 13, 2019 | TaiGen Biotechnology Co., Ltd. |
| NCT03593447 | Phase 2 | Mar 15, 2018 | Peking University, TaiGen Biotechnology Co., Ltd. |
| NCT03610880 | Phase 1 | Oct 17, 2017 | Central South University, R&G Pharma Studies Co.,Ltd., TaiGen Biotechnology Co., Ltd. |
| NCT03610867 | Phase 1 | Apr 27, 2017 | Central South University, R&G Pharma Studies Co.,Ltd., TaiGen Biotechnology Co., Ltd. |
| NCT02340962 | Phase 2 | May 1, 2015 | TaiGen Biotechnology Co., Ltd. |
| NCT02108418 | Phase 1 | Apr 1, 2014 | TaiGen Biotechnology Co., Ltd., WCCT Global |
| NCT01523990 | Phase 1 | Oct 1, 2011 | TaiGen Biotechnology Co., Ltd., WCCT Global |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TaiGen Biotechnology Co., Ltd. | For profit | 7 | 7 | 3 | 2011 |
| Central South University | Academic/Hospital | 2 | 0 | 1 | 2017 |
| R&G Pharma Studies Co.,Ltd. | For profit | 2 | 0 | 1 | 2017 |
| WCCT Global | For profit | 2 | 0 | 1 | 2011 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1